Skip to Content

Publications

Boyd, Douglas D.

  1. Yang L, Avila H, Wang H, Trevino J, Gallick GE, Kitadai Y, Sasaki T, Boyd DD. Plasticity in Urokinase-Type Plasminogen Activator Receptor (uPAR) Display in Colon Cancer Yields Metastable Subpopulations Oscillating in Cell Surface uPAR Density--Implications in Tumor Progression. Cancer Res 66(16):7957-67, 2006. PMID: 16912170.
  2. Wang H, Yan C, Asangani I, Allgayer H, Boyd DD. Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression. Oncogene 26:2058-2070, 2007. PMCID: PMC17001307.
  3. Yang, L., Hamilton, S.R, Sood, A, Kuwai, T., Ellis, L., Sanguino, A., Lopez-Berestin, G., and Boyd, D.D. The previously un-described ZKSCAN3 is a novel driver of colorectal cancer progression. Cancer Res 68:4321-4330, 2008. PMID: 18519692.
  4. Yang L, Zhang L. Wu Q, Boyd DD. Unbiased screening for transcriptional targets ofZKSCAN3 identifies integrin b4 and vascular endothelial growth factor as downstream targets. Journal of Biological Chemistry 283:35295-35304, 2008. PMCID: PMC2596387.
  5. Ishiguro T, Lin S-Y, Nakamura T, Yamamoto M, Boyd. D. Gene trapping identifies chloride channel 4 as a novel inducer of colon cancer cell migration, invasion and metastases. British Journal of Cancer 102(4):774-782, 2/2010. 

 Back to top

Calin, George A.

  1. Spizzo R, Nicoloso M, Croce CM, Calin GA. SnapShot: MicroRNAs in cancer. Cell 2009. May 1;137(3):586-586.e1.

  2. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, Wojcik SE, Ferdin J, Kunej T, Xiao L, Manoukian S, Secreto G, Ravagnani F, Wang X, Radice P, Croce CM, Davuluri RV, Calin GA. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res 70(7):2789-98, 4/2010. e-Pub 3/2010. PMCID: PMC2853025.
  3. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs - the micro steering wheel of tumour metastases. Nat Rev Cancer. e-Pub 3/2009. PMID: 19262572.

 Back to top

DuBois, Raymond N. / Wang, Dingzhi

  1. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10: 181-93. PMID: 20168319.
  2. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-8.
  3. Kim SH, Xia D, Kim SW, Holla V, Menter DG, Dubois RN. Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. Cancer Res 2010; 70: 4054-63. PMID: 20442290.
  4. Xia D, Holla VR, Wang D, Menter DG, DuBois RN. HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Res 2010; 70: 824-31. MID: 20068165.
  5. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 2010; 16: 1384-90.
  6. Wang D, Dubois RN, Richmond A. The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol 2009; 9: 688-96. PMID: 19734090  PMID: 20179228.
  7. Dubois RN. New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs. Cancer Prev Res (Phila Pa) 2009; 2: 285-7. PMID: 19336723.
  8. Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 2008; 68: 6468-76. PMID: 18676872.
  9. Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila Pa) 2008; 1: 93-9. PMID: 19138942.
  10. Backlund MG, Mann JR, Holla VR, et al. Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res 2008; 68: 9331-7. PMID: 19010907.

 Back to top

Ellis, Lee M.

  1. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren II G, Samuel S, Kim MP, Lim SH, Ellis LM. Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype and Increased Sensitivity to Insulin-like Growth Factor Receptor-1 Inhibition. Cancer Res 69(5): 1951-1957, 2009.
  2. Van Buren II G, Gray MJ, Dallas NA, Lim SJ, Fan F, Xia L, Mazar AP, Ellis LM. Targeting the urokinase plasminogen activator receptor (uPAR) with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer, 115(14):3360-3368, 2009.
  3. Kopetz SJ, Hoff PM, Morris JS, Wolff RA, Eng C, Glover K, Adinin R, Overman M,    Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach, JV. Phase II trial of infusional 5-Fluorouracil, irinotecan and bevacizumab (FOLFIRI+B) for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol, 28(3):453-459, 2009.
  4. Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 33 (5 Suppl 10): p. S1-7, 2006.
  5. Ellis LM, Curley SA, Grothey A.  Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol, 23(22): 4853-55, 2005.
  6. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.  Lancet Oncol, 11(4):373-382, 2010.
  7. Ellis LM, Rearon DA. Is there really a yin and yang to VEGF-targeted therapies? The Lancet Oncol, epub, July 14, 2010.
  8. Ellis LM, Haller D. Bevacizumab beyond progression: Does this make sense? J Clin Oncol, 26(33):5313-5, 2008.
  9. Ellis LM, Reardon, DA. The nuances of therapy. Nature 458:290-292, 2009.
  10. Ellis LM, Hicklin DJ. Pathways mediating resistance to VEGF-targeted therapy. Clin Cancer Res, 14(20):6371-5, 2008.

 Back to top

Eng, Cathy

  1. Eng C. Perspective: Are Herbal Medicines Ripe for the Cancer Clinic? Science Translational Medicine. Sci Transl Med. 2010 Aug 18;2(45):45ps41.PMID: 20720215.
  2. Eng C. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist. 2010;15(1):73-84. Epub 2010 Jan 12. Review.PMID: 20067946.
  3. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, Schrag D, Seidenfeld J, Benson AB 3rd. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010 Jan 20;28(3):493-508. Epub 2009 Oct 19. Review.PMID: 19841322.
  4. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):824-30. Epub 2009 May 21.PMID: 19464823.
  5. Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JM. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer. 2009 Dec 1;115(23):5432-40.PMID: 19673001.
  6.  Eng C. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009 Apr;6(4):207-18. Review.PMID: 19333227.
  7. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20;26(12):2000-5.PMID: 18421052.
  8. Eng C. K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2008 Mar;6(3):174-5. Review. No abstract available. PMID: 18391915.
  9. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 10;26(14):2311-9. Epub 2008 Apr 7.PMID: 18390971.
  10. Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, Hicks ME. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol. 2007 Dec;18(12):1588-91.PMID: 18057297.

 Back to top

Frazier, Marsha L.

  1. Wei C, Amos CI, Zhang N, Zhu J, Wang X, Frazier ML. Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model. Cancer Lett 277(2):149-54, 5/2009. e-Pub 1/2009. PMID 19147279.
  2. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med 6(5):e1000068, 5/2009. e-Pub 5/2009 PMID19536326: PMC2673042.
  3. Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier ML, Bruera E, Kurzrock R, Crane CH, Abbruzzese J, Evans D, Spitz MR. Genetic and non-genetic covariates of pain severity in patients with adenocarcinoma of the pancreas: Assessing the influence of cytokine genes. Journal of Pain and Symptom Management (JPS-D-08-00399R1), ePub ahead of print, 8/2009. PMID 19692203: PMC2795073.
  4. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S. MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood Based Biomarkers of Disease. Cancer Prev Res (Phila Pa) 2(2(9)):807-13, 9/2009. e-Pub 9/2009. PMID 19723895.
  5. Chen J, Etzel CJ, Amos CI, Zhang Q, Viscofsky N, Lindor NM, Lynch PM, Frazier ML. Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome. Cancer Causes Control 20(9):1769-77, 11/2009. e-Pub 8/2009. PMID 19690970.
  6. Zhu J, Sen S, Wei C, Frazier ML. Cyclin D1b represses breast cancer cell growth by antagonizing the action of cyclin D1a on estrogen receptor alpha-mediated transcription. Int J Oncol 36(1):39-48, 1/2010. PMID 19956831.
  7. Chen J, Amos CI, Merriman KW, Wei Q, Sen S, Killary AM, Frazier ML. Genetic variants of p21 and p27 and pancreatic cancer risk in non-Hispanic whites: a case-control study. Pancreas 39:1-4, 1/2010. PMID19910837: PMC2796289.
  8. Pande M, Lynch PM, Hopper JL, Jenkins MA, Gallinger S, Haile RW, LeMarchand L, Lindor NM, Campbell PT, Newcomb PA, Potter JD, Baron JA, Frazier ML, Amos CI. Smoking and colorectal cancer in Lynch syndrome: results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. Clin Cancer Res 16(4):1331-9, 2/2010. e-Pub 2/2010. PMID20145170: PMC2822883.
  9. Coolbaugh-Murphy MI, Xu JP, Ramagli LS, Ramagli BC, Brown BW, Lynch PM, Hamilton SR, Frazier ML, Siciliano MJ. Microsatellite instability in the peripheral blood leukocytes of HNPCC Patients. Hum Mutat 31(3):317-24, 3/2010. e-Pub 1/2010. PMID 20052760.
  10. Burton AM, Peterson SK, Marani SK, Vernon SW, Amos CI, Frazier ML, Lynch PM, Gritz ER. Health and lifestyle behaviors among persons at risk of Lynch syndrome. Cancer Causes Control 21(4):513-21, 4/2010. e-Pub 12/2009. PMID 20012181

 Back to top

Georgescu, Maria-Magdalena

  1. Morales FC, Takahashi Y, Kreimann EL, Georgescu M-M. Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 organizes ERM proteins at the apical membrane of polarized epithelia. Proc. Natl. Acad. Sci. USA 101:17705-10, 2004. PMID: 15591354.
  2. Takahashi Y, Morales, FC, Kreimann EL, Georgescu M-M. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J. 25(4): 910-920, 2006. PMID: 16456542.
  3. Morales FC, Takahashi Y, Momin S, Adams H, Chen X, Georgescu M-M. NHERF1/EBP50 head-to-tail intramolecular interaction masks the association with PDZ-domain ligands. Mol. Cell. Biol. 27:2527-37, 2007. PMID: 17242191.
  4. Kreimann EL, Morales FC, Takahashi Y, Adams H, Liu TJ, McCrea PD, Georgescu M-M. Cortical stabilization of -catenin contributes to NHERF1/EBP50 tumor suppressor function. Oncogene 26:5290-9, 2007. PMID: 17325659.
  5. Georgescu M-M, Morales FC, Molina JR, Hayashi Y. Roles of NHERF1/EBP50 in cancer. Review. Curr. Mol. Med., 8(6):459-68., 2008. PMID: 18781953
    Georgescu M-M. NHERF1: molecular brake on the PI3K pathway in breast cancer. Editorial. Breast Cancer Res. 10(2):106, 2008. PMID: 18430260.
  6. Morales FC, Molina JR, Hayashi Y, Georgescu M-M. Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro Oncol., 12(6):528-39, 2010. PMID: 20156804.
  7. Molina FC, Hayashi Y, Stephens C, Georgescu M-M. Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia, 12(6):453-63, 2010. PMID: 20563248.
  8. Molina JR, Morales FC, Hayashi Y, Aldape K, Georgescu M-M. Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. Cancer Res. Cancer Res. 2010 Aug 24. PMID: 20736378.
  9. Hayashi Y, Molina JR, Hamilton SR, Georgescu M-M. NHERF1 is a new marker in colorectal cancer progression. Neoplasia. In press 2010.

Back to top

Hamilton, Stanley R.

  1. Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DD.  The previously un-described ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. Cancer Research 68:4321-30, 2008.
  2. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL.  Stool DNA and occult blood testing for screen-detection of colorectal neoplasia. Annals of Internal Medicine 149:441-50, 2008.
  3. Sanchez AA, Wu TT, Prieto VG, Rashid A, Hamilton SR, Wang H. Comparison of primary and metastatic malignant melanoma of the esophagus: clinicopathologic review of 10 cases. Archives of Pathology and Laboratory Medicine 132:1723-9, 2008.
  4. Liang JJ, Wang H, Rashid A, Tan RH, Hwang RF, Hamilton SR, Abbruzzese JL, Evans DB, Wang H. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clinical Cancer Research 14:7043-9, 2008.
  5. Wang H, Song X, Logsdon C, Zhou G, Evans DB, Abbruzzese JL, Hamilton SR, Tan TH, Wang H. Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer. Cancer Research 69:1063-70, 2009.
  6. Bartley AN, Thompson PA, Buckmeier JA, Kepler CY, Hsu CH, Snyder MS, Lance P, Bhattacharyya A, Hamilton SR. Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps. Modern Patholology 23:169-76, 2010. e-Pub 10/2009.
  7. Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, Hamilton SR, Zhang W. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Laboratory Investigation 89(5):531-48, 5/2009. e-Pub 3/2009.
  8. Konishi K, Shen L, Jelinek J, Watanabe Y, Ahmed S, Kaneko K, Kogo M, Takano T, Imawari M, Hamilton SR, Issa JP. Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prevention Research (Phila Pa) 2(9):814-22, 9/2009. e-Pub 9/2009.
  9. De Jesus-Monge WE, Gonzalez-Keelan C, Zhao R, Hamilton SR, Rodriguez-Bigas M, Cruz-Correa M. Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico. Familial Cancer 9:155-166, 2010.
  10. Sargent D, et al, Defective mismatch repair as a predictive marker for lack of efficacy of 5-FU-based adjuvant therapy in colon cancer, Journal of Clinical Oncology. 2010 [accepted].

 Back to top

Hawk, Ernest

  1. Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Burke CA. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010 Jun;105(6):1437-43. Epub 2010 Mar 16. PubMed PMID: 20234350.
  2. Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG; Adenoma Prevention with Celecoxib (APC) Study Investigators. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila Pa). 2010 May;3(5):588-96. Epub 2010 Apr 19. PubMed PMID: 20403998.
  3. Hawk E, Patterson S. Aspirin: anticolorectal adenocarcinoma activity in the adjuvant arena? Future Oncol. 2010 Feb;6(2):197-200. PubMed PMID: 20146578.
  4. Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res. 2009 Jul 1;69(13):5269-84. Epub 2009 Jun 2. Review. PubMed PMID: 19491253.
  5. Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. 2009Jun;136(7):2127-2136.e1. Epub 2009 Feb 21. PubMed PMID: 19233181; PubMed Central PMCID: PMC2693443.
  6. Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Seligson D, Charabaty A, Chia D, Umar A, Viner J, Hawk E, Pinsky PF. A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol. 2009 May;7(5):568-74. PubMed PMID: 19418605.
  7. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa). 2009 Apr;2(4):310-21. Epub 2009 Mar 31. PubMed PMID: 19336730.
  8. Mutch MG, Mph RE, Fleshman JW, Rall CJ, Dry S, Seligson D, Charabaty A, Chia D, Dvm AU, Viner J, Hawk E, Pinsky PF. A Multi-Center Study of Prevalence and Risk Factors for Aberrant Crypt Foci. Clin Gastroenterol Hepatol. 2009 Feb 3.[Epub ahead of print] PubMed PMID: 19558990.
  9. Hawk E, Guillem JG. Improving the vision of colonoscopy: does the fine print really matter? Cancer Prev Res (Phila Pa). 2008 Dec;1(7):495-8. PubMed PMID: 19138997.
  10. Hawk ET, Greenwood A, Gritz ER, McTiernan A, Sellers T, Hursting SD, Leischow S, Grad O; Translational Research Working Group. The Translational Research Working Group developmental pathway for lifestyle alterations. Clin Cancer Res. 2008 Sep 15;14(18):5707-13. PubMed PMID: 18794079.

 Back to top

Hung, Mien-Chie 

  1. Ding, Q., Xia W., Liu, J-C., Yang, J-Y., Lee, D-F., Xia, J., Bartholomeusz, Li, Y., Pan, Y., Li, Z., Bargou, RC., Qin, J., Lai, C-C., Tsai, F-J. Tsai, C-H. and Hung, M-C.  Erk1/2 associates with and primes GSK-3 for its inactivation resulting in upregulation of -catenin. Mol. Cell 19:159-170, 2005. PMID: 16039586.
  2. Ou-Yang, F., Lan, K-L., Chen, C-T., Liu, J-C., Weng, C-L., Chou, C-K., Xie, X., Hung, J-Y., Wei, Y., Hortobagyi G.N. and Hung, M-C. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting cancerous neovascular endothelial cells. Cancer Res. 66: 378-384, 2006. PMID: 16397252.
  3. Lee, D-F., Kuo, H-P., Chen, C-T., Hsu, J-M., Sun, H-L., Chou, C-K., Wei, Y., Li, L-Y.,Ping, B., Huang, W-C., He, X., Hung, J-Y., Lai, C-C., Ding, Q., Su, J-L., Yang, J-Y., Sahin, A.A., Hortobagyi, G.N., Tsai, F-J., Tsai, C-H. and Hung, M-C. IKK suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell, 130:440-455, 2007. PMID: 17693255.
  4. Lee, D-F., Kuo, H-P., Liu, M., Chou, C-K., Xia, W., Du, Y., Shen, J., Shen, J., Chen, C-T., Huo, L., Hsu, M-C., Li, C-W., Ding, Q., Liao, T-L., Lai, C-C., Lin, A-C. Chang, Y-H, Tsai, S-F., Li, L-Y. and Hung, M-C. KEAP1 E3 ligase-mediated down regulation of NF-B signaling by targeting IKK. Mol Cell 36: 131-140, 2009. *select as the cover of issue of Oct 9, 2009. NIHMS153233, PMC2770835.
  5. Kuo, H-P., Lee, D-F., Chen, C-T., Liu, M., Chou, C-K., Lee, H-J., Xie, X., Wei, Y., Xia, W., Zhang, W., Yi, D., Yang, J-Y., Huang, T-H., Yen,C-J., Tan, M., Xing, G., Zhao, Y., Lin, C-H., Tsai, S-F., Fidler, IJ and Hung, M-C. ARD1 stabilization of TSC2 suppresses tumorigenesis via the mTOR signaling pathway. Science Signaling 3 (108): ra9, 2010. NIHMS 198006, PMC2874891.

 Back to top

Issa, Jean-Pierre J.

  1. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, Hamilton SR, Issa JP. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A. 104(47):18654-9, 2007.
  2. Wang J, Bhutani M, Pathak AK, Lang W, Ren H, Jelinek J, He R, Shen L, Issa JP, Mao L.  Delta DNMT3B variants regulate DNA methylation in a promoter-specific manner. Cancer Res 67(22):10647-52, 2007.
  3. Oki Y, Issa JP. Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. Int J Hematol 86(4):306-14, 2007.
  4. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood. 2007 Nov 30; [Epub ahead of print]
  5. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 67(23):11335-43, 2007.
  6. Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S, Shi Y, Ling X, Watt JC, Tsutsumi-Ishii Y, Ohsaka A, Nagaoka I, Issa JP, Kogan SC, Andreeff M. PPARgamma-Active Triterpenoid CDDO Enhances ATRA-Induced Differentiation in APL. Cancer Biol Ther 6(12), 2007.
  7. Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, Shureiqi I. 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. FASEB J. 2008 Jan 15; [Epub ahead of print]
  8. Kondo Y, Shen L, Cheng A, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold D, Sekido Y, Huang T, Issa JP. Gene silencing in cancer by histone H3 lysine 27 tri-methylation independent of promoter DNA methylation. Nature Genetics 40(6):741-50, 2008.
  9. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, Wei Y, Jelinek J, Issa JP, Garcia-Manero G. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia. 2008 Jun 5. [Epub ahead of print]
  10. Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP.  Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.Blood. 2008 Jun 3. [Epub ahead of print].

 Back to top

Kopetz, Scott

  1. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102(1):144-50, 01/05/2010, 1/2010. PMID: 19935793.
  2. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology 28(3):453-9, 1/2010. PMID: 20008624.
  3. Chun YS, Boonsirikamchai P, Maru DM, Kopetz S, Charnsangavej C, Abdalla EK, Wang H, Kishi Y, Palavecino M, Kaur H, Raval B, Vauthey JN, Loyer EM. Novel CT response criteria to bevacizumab-containing chemotherapy in colorectal liver metastases correlate with clinical and pathologic response. JAMA 302(21):2338-44, 12/2009. PMID: 19952320.
  4. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8(4):225-30, 10/2009. PMID: 19822514.
  5. Kopetz S, Chang G, Overman M, Eng C, Larson DW, Grothey A, Vauthey JN, Sargent D, McWilliams R. Improved Survival in Metastatic Colorectal Cancer is Associated with Sequential Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 8/1/2009. e-Pub 5/26/2009. PMCID: PMC2720081.
  6. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P. Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. Int J Radiat Oncol Biol Phys 74(3):818-23, 7/1/2009. e-Pub 1/13/2009. PMID: 19147305.
  7. Rossi S, Kopetz S, Davuluri R, Hamilton SR, Calin GA. MicroRNAs, ultraconserved genes and colorectal cancers. Int J Biochem Cell Biol, 6/2/2009. e-Pub 6/2/2009. PMID: 19497386.
  8. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 26(15S):4538, 6/1/2009. e-Pub 1/21/2009. PMID: 19164203.
  9. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE.. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842-9, 5/2009. e-Pub 4/2009. PMCID: PMC2709758.
  10. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614-22, 3/2009. e-Pub 1/8/2009. PMID: 19130139.

 Back to top

Krishnan, Sunil

  1. Jones BL, Krishnan S, Cho SH. Estimation of microscopic dose enhancement factor around gold nanoparticles by Monte Carlo calculations. Med Phys 37(7): 3809-3816, 2010.
  2. Krishnan S, Diagaradjane P, Cho SH. Nanoparticle-mediated thermal therapy: Evolving strategies for prostate cancer therapy. Int J Hyperthermia 2010 (in press).
  3. Diagaradjane P, Deorukhkar A, Gelovani JG, Maru DM, Krishnan S. Gadolinium chloride augments tumor-specific imaging of targeted quantum dots in vivo. ACS Nano 2010 Jun 29. [Epub ahead of print]
  4. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 2009 May 21. [Epub ahead of print]
  5. Callender GG, Das P, Rodriguez-Bigas MA, Skibber JM, Crane CH, Krishnan S, Delclos ME, Feig BW. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol. 2009 Oct 22. [Epub ahead of print]
  6. Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Bedi M, Krishnan S, Crane CH. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys. 2009 Aug 19. [Epub ahead of print]
  7. Silberfein EJ, Kattepogu KM, Hu C-Y, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol 2010 (in press).
  8. Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal BB, Krishnan S. Curcumin sensitizes human colorectal cancer xenografts in nude mice to γ-radiation by targeting NF-κB-regulated gene products. Clin Cancer Res 14(7):2128-36, 2008.
  9. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, Gelovani J, Guha S, Krishnan S, Aggarwal BB. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 125(9):2187-97, 2009.
  10. Sandur SK, Deorukhkar A, Pandey MK, Pabón AM, Shentu S, Guha S, Aggarwal BB, Krishnan S. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-B activity. Int J Radiat Oncol Biol Phys 75(2): 534-42, 2009.

Back to top

Lynch, Patrick M.

  1. Pande M, Lynch PM, Hopper JL, Jenkins MA, Gallinger S, Haile RW, Lemarchand L, Lindor NM, Campbell PT, Newcomb PA, Potter JD, Baron JA, Frazier ML, Amos CI. Smoking and Colorectal Cancer in Lynch Syndrome: Results from the Colon Cancer Family Registry and The University of Texas M.D. Anderson Cancer Center. Clin Cancer Res 16(4):1331-1339, 2/2010. e-Pub 2/2010. PMCID: PMC2822883.
  2. Chen J, Etzel CJ, Amos CI, Zhang Q, Viscofsky N, Lindor NM, Lynch PM, Frazier ML. Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome. Cancer Causes Control 20(9):1769-77, 11/2009. e-Pub 8/2009. PMID: 19690970.
  3. Lynch PM. The hMSH2 and hMLH1 genes in hereditary nonpolyposis colorectal cancer. Surg Oncol Clin N Am 18(4):611-24, 10/2009. PMID: 19793569.
  4. HT Lynch, PM Lynch, SJ Lanspa, CL Snyder, JF Lynch, CR Boland. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76:1-18, 2009.
  5. Pande M, Amos CI, Osterwisch DR, Chen J, Lynch PM, Broaddus R, Frazier ML. Genetic variation in genes for the xenobiotic-metabolizing enzymes CYP1A1, EPHX1, GSTM1, GSTT1, and GSTP1 and susceptibility to colorectal cancer in Lynch syndrome. Cancer Epidemiol Biomarkers Prev 17(9):2393-401, 9/2008. PMID: 18768509.
  6. Lynch PM. Chemoprevention with special reference to inherited colorectal cancer. Fam Cancer 7(1):59-64, 2008. PMID: 17680350.
  7. Lynch PM. Standards of care in diagnosis and testing for hereditary colon cancer. Fam Cancer 7(1):65-72, 2008. PMID: 17701450.
  8. Lynch PM. New issues in genetic counseling of hereditary colon cancer. Clin Cancer Res 13(22 Pt 2):6857s-61s, 11/2007. PMID: 18006790.
  9. Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris J, Pisters PW, Feig B, Sunder PK, Izzo JG, Ajani JA. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer 110(5):989-95, 9/2007. e-Pub 7/2007. PMID: 17636525.
  10. Pande M, Chen J, Amos CI, Lynch PM, Broaddus R, Frazier ML. Influence of methylenetetrahydrofolate reductase gene polymorphisms C677T and A1298C on age-associated risk for colorectal cancer in a caucasian lynch syndrome population. Cancer Epidemiol Biomarkers Prev 16(9):1753-9, 9/2007. PMID: 17855693.

 Back to top

Morris, Jeffrey

  1. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SM. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res 65(24):11486-92, 12/2005.
  2. Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi I. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 25(8):1225-41, 2/2006.
  3. Lin EH, Curley SA, Crane CC, Feig B, Skibber J, Delcos M, Vadhan SR, Morris J, Ayers GD, Ross A, Brown T, Rodriguez-Bigas MA, Janjan N. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol 29(3):232-9, 6/2006.
  4. Chan AO, Jim MH, Lam KF, Morris JS, Siu DC, Tong T, Ng FH, Wong SY, Hui WM, Chan CK, Lai KC, Cheung TK, Chan P, Wong G, Yuen MF, Lau YK, Lee S, Szeto ML, Wong BC, Lam SK. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 298(12):1412-9, 9/2007.
  5. Suehiro Y, Wong CW, Chirieac LR, Kondo Y, Shen L, Webb CR, Chan YW, Chan AS, Chan TL, Wu TT, Rashid A, Hamanaka Y, Hinoda Y, Shannon RL, Wang X, Morris J, Issa JP, Yuen ST, Leung SY, Hamilton SR. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res 14(9):2560-9, 5/2008.
  6. Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I. Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther 16(5):886-92, 5/2008. e-Pub 3/2008. PMCID: PMC2377397.
  7. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 301(24):2553-62, 6/2009. PMCID: PMC2760963.
  8. Zuo X, Peng Z, Moussalli MJ, Morris JS, Boraddus RR, Fischer SM, and Shureiqi I. Targeted PPAR-δ generic disruption profoundly inhibits colon tumorigenesis. Journal of the National Cancer Institute 101(10):762-767, 2009.
  9. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol. e-Pub.
  10. Shureiqi I, Chen D, Day RS, Hochman FL, Ross W, Cole RA, Moy O, Morris JS, Xiao L, Newman R, Yang P, and Lippman SM (2010). Profiling Lipoxygenase Metabolism in Specific Steps of Colonic Tumorigenesis. Cancer Prevention Research, published online June 22, 2010 (PMID: 20570882).

 Back to top

Powis, Garth

  1. Ihle NT and Powis G. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol Aspects Med 31(2):135-144, 4/2010. PMCID: PMC2877630.
  2. Meuillet EM, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirpatrick DL and Powis G. Molecular pharmacology and antitumor activity of PHT-427, a Novel AKT/PDPK1 pleckstrin homology domain inhibitor. Mol Cancer Ther 9:706-717, 3/2010. PMCID: PMC2837366.
  3. Du-Cuny L, Zuohe S, Moses S, Powis G, Mash EA, Meuillet EJ and Zhang S. Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem 17(19):6893-6992, 10/2009. e-Pub 8/2009. PMCID: PMC2808703.
  4. Koh MY, Spivak-Kroizman TR and Powis G. Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clin Cancer Res 15(19):5945-5946, 10/2009. e-Pub 9/2009. PMCID: PMC2760048.
  5. Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, Ihle N, Skillman AG, Zhang S, Mash EA, Powis G, Meuillet EJ. In vitro and In vivo activity of novel small-molecule inhibitors targeting the Pleckstrin Homology Domain of Protein Kinase B/AKT. Cancer Res 69(12):5073-5081, 6/2009. e-Pub 6/2009. NIHMSID: NIHMS200827.
  6. Koh M and Powis G. HAF: the new player in oxygen-independent HIF-1 alpha degradation. Cell Cycle 8(9):1359-1366, 5/2009. PMCID: PMC2700049.

  7. Bartholomeusz G, Cherukuri P, Kingston J, Cognet L, Lemos R, Leeuw TK, Gumbiner-Russo L, Weisman RB, Powis G. In-vivo therapeutic silencing of HIF-1(alpha) using single-walled carbon nanotubes noncovalently coated with siRNA. Nano Research 2(4):279-291, 4/2009. PMCID: PMC2801079.
  8. James BP, Staatz WD, Wilkinson ST, Meuillet EJ, Powis G. Superoxide dismutase is regulated by the LAMMER kinase in Drosophila and human cells. Free Radic Biol Med 46:821-827, 3/2009. PMCID: PMC2699669.
  9. Ihle NT, Lemos R, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69(1):143-150, 1/2009. PMCID: PMC2613546.
  10. Ihle NT, Lemos R, Schwartz D, Oh J, Halter RJ, Wipf P, Kirkpatrick L, Powis G. Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Mol Cancer Ther 8(1):94-100, 1/2009. PMCID: PMC2633941.

 Back to top

Wu, Xiangwei

  1. Ren X, Xu Z, Myers JN, Wu, X. Bypass NFkappaB-Mediated Survival Pathways by TRAIL and Smac. Cancer Biol Ther 6(7)(7), 2007. e-Pub 3/2007. PMID: 17611406.
  2. Deng, Y, Ren, X, Lin, Y., Yang, L., and Wu, X. A JNK-dependent pathway is required for TNFa-induced apoptosis. Cell 115:61-70, 2004.
  3. Wu, X. and Deng, Y. Bax and BH3-Domain- Only Proteins in in p53-Apoptosis. Frontiers in Bioscience 7:151-156, 2002.
  4. Deng Y., Lin, Y., and Wu, X. Trail Induced Apoptosis Requires Bax-Dependent Mitochondrial Release of Smac/DIABLO. Genes & Develop 16:33-45, 2002.
  5. Deng, Y. and Wu, X. Peg3/Pw1 Promotes p53-Mediated Apoptosis by Inducing Bax Translocation from Cytosol to Mitochondria. Proc Natl Acad Sci USA 97(22):12050-12055, Oct. 24, 2000. PMCID: PMC11050235.

 Back to top

Find Clinical Trials

Clinical trials are research studies that test new cancer drugs, diagnostic procedures and therapies on humans.


© 2014 The University of Texas MD Anderson Cancer Center